397 related articles for article (PubMed ID: 17182091)
1. Modeling the therapeutic efficacy of p53 restoration in tumors.
Martins CP; Brown-Swigart L; Evan GI
Cell; 2006 Dec; 127(7):1323-34. PubMed ID: 17182091
[TBL] [Abstract][Full Text] [Related]
2. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
3. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
4. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrially targeted p53 has tumor suppressor activities in vivo.
Talos F; Petrenko O; Mena P; Moll UM
Cancer Res; 2005 Nov; 65(21):9971-81. PubMed ID: 16267022
[TBL] [Abstract][Full Text] [Related]
6. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
7. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
8. C-myc overexpression and p53 loss cooperate to promote genomic instability.
Yin XY; Grove L; Datta NS; Long MW; Prochownik EV
Oncogene; 1999 Feb; 18(5):1177-84. PubMed ID: 10022123
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of aberrant Y chromosomes in gamma-ray-induced thymic lymphomas lacking p53.
Chou D; Matsuki J; Saitou Y; Kosugi SI; Shinbo T; Gejyo F; Niwa O; Kominami R
Mol Carcinog; 1999 Nov; 26(3):157-62. PubMed ID: 10559790
[TBL] [Abstract][Full Text] [Related]
10. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
Christophorou MA; Ringshausen I; Finch AJ; Swigart LB; Evan GI
Nature; 2006 Sep; 443(7108):214-7. PubMed ID: 16957739
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy.
Klimovich B; Mutlu S; Schneikert J; Elmshäuser S; Klimovich M; Nist A; Mernberger M; Timofeev O; Stiewe T
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22288-22293. PubMed ID: 31611375
[TBL] [Abstract][Full Text] [Related]
12. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
13. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
15. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
Wiseman A
Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
[No Abstract] [Full Text] [Related]
16. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
Bertwistle D; Sherr CJ
Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
20. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.
Inoue K; Zindy F; Randle DH; Rehg JE; Sherr CJ
Genes Dev; 2001 Nov; 15(22):2934-9. PubMed ID: 11711428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
